Skip to main content
HLB bioStep Co.,Ltd. logo

HLB bioStep Co.,Ltd. — Investor Relations & Filings

Ticker · 278650 ISIN · KR7278650007 KO Professional, scientific and technical activities
Open in API
Filings indexed 326 across all filing types
Latest filing 2024-04-15 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 278650

About HLB bioStep Co.,Ltd.

http://hlbbiostep.com/en/

HLB bioStep Co.,Ltd. is a non-clinical Contract Research Organization (CRO) that provides a range of testing services to pharmaceutical companies and bio ventures. The company's core services support new drug development and include efficacy testing, pharmacokinetic/toxicokinetic (PK/TK) studies, and toxicology evaluations. A key area of specialization is veterinary medicine; HLB bioStep is an institution approved to conduct non-clinical tests and clinical trials for veterinary drugs. It also offers consulting services for regulatory approval procedures. The company utilizes various platform technologies, such as cell-enzyme-based screening and xenograft assays, and provides a comprehensive 'One-Stop Service' that leverages its experience in building laboratory facilities.

Recent filings

Filing Released Lang Actions
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from HLB Life Science Step (HLB바이오스텝) regarding the adjustment of the conversion price (전환가액의 조정) for convertible bonds. This type of filing is a standard corporate disclosure related to capital structure and financing instruments, which falls under the 'Capital/Financing Update' category as it directly impacts the company's debt-to-equity conversion terms.
2024-04-15 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the change in share ownership by Korea Securities Finance Corp in HLB BioStep. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-04-09 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Financial Investment Services and Capital Markets Act. It details changes in share ownership (specifically by Kim Do-hyung regarding HLB Biostep) and includes specific sections for reporting major shareholding notifications, changes in shareholding, and collateral agreements. This falls under the 'Major Shareholding Notification' category.
2024-04-01 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results from a General Meeting of Shareholders (Annual General Meeting). It details the approval of financial statements, dividend resolutions, director appointments, and amendments to business purposes. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2024-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from HLB BioStep. It provides a summary of the audit opinion (unqualified/proper), key financial data (assets, liabilities, equity, revenue, profit/loss), and details regarding the external auditor (Samjong Accounting Corp). While it contains financial data, it is a standard regulatory disclosure form used in the Korean market to announce the completion and submission of the audit report to the exchange, rather than the full annual report document itself. Therefore, it is classified as an Audit Report/Information filing. FY 2023
2024-03-19 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the fiscal year 2023, prepared by Samjong KPMG for HLB BioStep. It includes the independent auditor's opinion, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and notes to the financial statements. It is not an Annual Report (10-K) as it lacks the comprehensive management discussion and analysis (MD&A) and business overview typically found in a full 10-K, and it is not an announcement (RPA) because it contains the full financial data and audit opinion. FY 2023
2024-03-19 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.